小细胞肺癌脑转移未行全脑放疗 upfront SRS 的荟萃分析
该荟萃分析纳入9项观察性研究共1638例小细胞肺癌脑转移患者,评估未行全脑放疗 upfront SRS 的疗效并与 WBRT 比较。结果显示 SRS 组12个月总生存率39%,优于 WBRT 的29%(RR 1.33,P=0.0001),局部控制率93%,支持对高度筛选患者行 upfront SRS。
要点
- upfront SRS 的12个月 OS 率为39%,WBRT 为29%,SRS 更优。
- 12个月局部控制率达93%,远脑失败率41%。
- SRS 后挽救治疗中 SRS 占32%,WBRT 占19%。
核心结论
- 对高度筛选的局限脑转移 SCLC 患者,upfront SRS 可获得较好的病灶控制和生存结局。
- 结果支持设计随机临床试验以确认 SRS 在该场景中的作用。
研究设计与样本
- 遵循 PRISMA 和 MOOSE 指南的系统综述与荟萃分析。
- 检索 Medline、Embase、Cochrane Library 及年会论文集至2020年7月1日。
- 纳入9项观察性研究,共1638例患者。
主要发现
- 中位总生存期为8.3个月(95%CI 7.1-9.5个月,I2=0%)。
- 12个月总生存率为39%(95%CI 31-44%,I2=0%)。
- SRS 与 WBRT 的12个月 OS 相对风险为1.33(95%CI 1.13-1.51,P=0.0001)。
- SRS 对比 WBRT 的6、12、18、24个月 OS 分别为67% vs 57%、39% vs 29%、22% vs 15%、15% vs 9%(P<0.001)。
- 12个月局部控制率为93%(95%CI 91-94%,I2=0%),远脑失败率为41%(95%CI 33-48%,I2=52%,P=0.08),12个月无神经死亡生存率为87%(95%CI 84-89%)。
关键数值与推荐
- upfront SRS 后挽救治疗采用 SRS 的比例为32%,采用 WBRT 的比例为19%。
临床怎么用
- 对高度筛选的局限脑转移 SCLC 患者,可考虑 upfront SRS 作为治疗选择。
局限性
- 基于回顾性观察性研究的汇总,证据等级有限。
- 需要随机临床试验进一步确认 SRS 的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Assess upfront Stereotactic radiosurgery (SRS) effectiveness for small cell lung cancer (SCLC) brain metastases (BM). Where possible, a comparison with whole-brain radiotherapy (WBRT) was performed. METHODS: Following PRISMA and MOOSE guidelines, eligible studies were identified on Medline, Embase, Cochrane Library, and proceedings of annual meetings between inception and July 01, 2020. RESULTS: Nine observational studies with 1638 patients were included. The median overall survival (OS) was 8.3 months (95% CI 7.1-9.5 months, I2 = 0%). OS rate at 12 months was 39% (95% CI 31-44%, I2 = 0%). The relative risk between SRS and WBRT for the OS at 12 months was 1.33 (95% CI 1.13-1.51, P = 0.0001). The projected OS for 6, 12, 18- and 24-months comparing SRS with WBRT was 67% vs. 57%, 39% vs. 29%, 22% vs. 15% and 15% vs 9%, favoring SRS (P < 0.001). The LC rate at 12 months was 93% (95% CI 91-94%, I2 = 0%). The distant brain failure rate (DBFR) at 12 months was 41% (95% CI 33-48%, I2 = 52%, P = 0.08). The SRS or WBRT as salvage treatment after upfront SRS was 32% and 19%, respectively. The freedom from neurologic death at 12 months was 87% (95% CI 84-89%). CONCLUSION: Based on the pooling of a large sample of retrospective studies our meta-analysis suggests that for high selected SCLC patients with limited BM upfront SRS produces favorable lesion control and survival outcomes. These findings support the design of randomized clinical trial to confirm the role of SRS in this clinical scenario.
引用
- Viani GA, Gouveia AG, Louie AV, et al. Stereotactic radiosurgery for brain metastases from small cell lung cancer without prior whole-brain radiotherapy: A meta-analysis. Radiother Oncol. 2021. PMID: 34171453. doi:10.1016/j.radonc.2021.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。